Format

Send to

Choose Destination
See comment in PubMed Commons below
Clin Immunol. 2013 Sep;148(3):359-68. doi: 10.1016/j.clim.2012.09.009. Epub 2012 Oct 2.

Small molecules in the treatment of systemic lupus erythematosus.

Author information

1
Division of Rheumatology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA.

Abstract

Advances in the understanding of the cellular biological events that underlie systemic lupus erythematosus (SLE) have led to the identification of key molecules and signaling pathways that are aberrantly expressed. The parallel development of small molecule drugs that inhibit or interfere with the specific perturbations identified, offers perspective for more rational, effective and less toxic therapy. In this review, we present data from preclinical and clinical studies of such emerging novel therapies with a particular focus on kinase inhibitors and other compounds that modulate signal transduction. Moreover, we highlight the use of chromatin-modifying medications, bringing attention to the central role of epigenetics in SLE pathogenesis.

KEYWORDS:

HDAC inhibitors; Jak; Kinase inhibitors; Syk; Systemic lupus erythematosus

PMID:
23158694
PMCID:
PMC3587286
DOI:
10.1016/j.clim.2012.09.009
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science Icon for PubMed Central
    Loading ...
    Support Center